Paul-Peter Tak
Chief Executive Officer presso CANDEL THERAPEUTICS, INC.
Patrimonio netto: 590 218 $ in data 31/03/2024
Profilo
Paul-Peter Tak is the founder of Sitryx Therapeutics Ltd.
(founded in 2018) and holds the title of Director.
He is also the founder of MeiraGTx Netherlands BV.
Dr. Tak's current job(s) include being the President, Chief Executive Officer & Director at Candel Therapeutics, Inc. (since 2020), Chairman at Citryll BV (since 2023), and Director at Levicept Ltd.
(since 2018).
Dr. Tak's former job(s) include being the President & Chief Executive Officer at Tempero Pharmaceuticals, Inc. (2012-2015), President & Chief Executive Officer at Senda Biosciences, Inc. (2018-2020), Director at ViiV Healthcare Ltd.
(2015-2018), Director at Galvani Bioelectronics Ltd.
(2016-2018), Director at Omega Therapeutics, Inc. (2018-2020), Chief Immunology Officer & Senior Vice President at GSK Plc (2011-2018), Venture Partner at Flagship Pioneering (2018-2020), Clinical Associate Professor at the University of California San Diego (1999-2004), and Professor at the University of Amsterdam (1999-2011).
Dr. Tak's education includes a doctorate from Vrije Universiteit Amsterdam.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
28/11/2023 | 373 556 ( 1.29% ) | 590 218 $ | 31/03/2024 |
Posizioni attive di Paul-Peter Tak
Società | Posizione | Inizio |
---|---|---|
CANDEL THERAPEUTICS, INC. | Chief Executive Officer | 01/09/2020 |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Founder | 01/01/2018 |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Director/Board Member | 01/09/2018 |
Citryll BV
Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest. | Chairman | 30/03/2023 |
Precedenti posizioni note di Paul-Peter Tak
Società | Posizione | Fine |
---|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/06/2020 |
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/06/2020 |
OMEGA THERAPEUTICS, INC. | Director/Board Member | 01/06/2020 |
Galvani Bioelectronics Ltd.
Galvani Bioelectronics Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The private company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy. | Director/Board Member | 01/09/2018 |
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Director/Board Member | 31/08/2018 |
Formazione di Paul-Peter Tak
Vrije Universiteit Amsterdam | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
GSK PLC | Health Technology |
CANDEL THERAPEUTICS, INC. | Health Technology |
OMEGA THERAPEUTICS, INC. | Health Technology |
Aziende private | 9 |
---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Health Technology |
Tempero Pharmaceuticals, Inc. | Commercial Services |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Health Technology |
MeiraGTx Netherlands BV
MeiraGTx Netherlands BV Pharmaceuticals: MajorHealth Technology MeiraGTx Netherlands BV operates as a biopharmaceutical company developing local gene therapy for inflammatory diseases. It is into develop adeno-associated viral mediated gene therapy for patients with rheumatic conditions. The company was founded in 2005 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Galvani Bioelectronics Ltd.
Galvani Bioelectronics Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Galvani Bioelectronics Ltd. is a pioneering research and British development company founded in 2016, dedicated to bringing bioelectronic therapies to patients. The private company is based in Stevenage, UK. Galvani Bioelectronics combines GSK's therapeutics discovery and development knowledge with Verily's expertise in software and electronics for clinical applications. The company is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through the use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy. | Health Technology |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
Citryll BV
Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest. | Commercial Services |
Senda Biosciences, Inc.
Senda Biosciences, Inc. BiotechnologyHealth Technology Kintai Therapeutics, Inc. engages in discovering and development of precision enteric medicine. It offers discovery platform, enteric biology and analytics, and precision enteric medicines. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Paul-Peter Tak